Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $4.40 USD
Change Today -0.10 / -2.22%
Volume 645.0K
As of 8:10 PM 04/17/15 All times are local (Market data is delayed by at least 15 minutes).

threshold pharmaceuticals (THLD) Snapshot

Open
$4.43
Previous Close
$4.50
Day High
$4.49
Day Low
$4.36
52 Week High
09/9/14 - $5.41
52 Week Low
11/7/14 - $2.58
Market Cap
313.9M
Average Volume 10 Days
423.4K
EPS TTM
$-0.35
Shares Outstanding
71.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for THRESHOLD PHARMACEUTICALS (THLD)

threshold pharmaceuticals (THLD) Related Businessweek News

No Related Businessweek News Found

threshold pharmaceuticals (THLD) Details

Threshold Pharmaceuticals, Inc., a biotechnology company, discovers and develops therapeutic agents that target tumor cells for the treatment of patients living with cancer in the United States. Its lead investigational small molecule is evofosfamide, which is in two Phase III clinical trials for the treatment of soft tissue sarcoma indication and pancreatic cancer; Phase II clinical trials for treating non-squamous non-small cell lung cancer; Phase II clinical trials for advanced melanoma and soft tissue sarcoma; Phase I/II clinical trials for multiple myeloma and pancreatic cancer; and Phase I clinical trials for the treatment of solid tumors, pancreatic cancer, and advanced solid tumors. The company is also involved in the study of evofosfamide in investigator sponsored trials, including Phase I/II clinical trials for glioblastoma; Phase II clinical trials for glioblastoma and pancreatic neuroendocrine tumors; and Phase I clinical trials for advanced kidney cancer or liver cancer. In addition, it engages in developing antiangiogenic therapies in various tumor types in human clinical trials; TH-4000, an investigational hypoxia-activated EGFR tyrosine kinase inhibitor; and [18F]-HX4, an investigational PET imaging agent for hypoxia. The company has a license and co-development agreement with Merck KGaA to co-develop and commercialize evofosfamide; license agreement with Auckland UniServices Ltd. for the development program based on TH-4000; and license agreement with Eleison Pharmaceuticals, Inc. for the manufacture, development, and commercialization of glufosfamide for the treatment of cancer in humans and animals, as well as other uses. Threshold Pharmaceuticals, Inc. was founded in 2001 and is headquartered in South San Francisco, California.

61 Employees
Last Reported Date: 03/3/15
Founded in 2001

threshold pharmaceuticals (THLD) Top Compensated Officers

Executive Chairman and Chief Executive Office...
Total Annual Compensation: $575.0K
Vice President of Finance and Controller
Total Annual Compensation: $273.0K
Chief Medical Officer
Total Annual Compensation: $395.0K
Senior Vice President of Regulatory Affairs &...
Total Annual Compensation: $320.0K
Senior Vice President of Pharmaceutical Devel...
Total Annual Compensation: $290.0K
Compensation as of Fiscal Year 2014.

threshold pharmaceuticals (THLD) Key Developments

Threshold Pharmaceuticals Inc. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2014; Provides Clinical Outlook Related to the Development of Evofosfamide

Threshold Pharmaceuticals Inc. announced unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, the company reported revenue of $3,681,000 against $3,212,000 a year ago. Loss from operations was $7,551,000 against $7,774,000 a year ago. Loss before provision for taxes was $5,964,000 against $7,508,000 a year ago. Net loss was $5,964,000 or $0.12 per diluted share against $7,589,000 or $0.13 per diluted share a year ago. For the year, the company reported revenue of $14,722,000 against $12,495,000 a year ago. Loss from operations was $31,251,000 against $26,024,000 a year ago. Loss before provision for taxes was $21,584,000 against $28,213,000 a year ago. Net loss was $21,584,000 or $0.49 per diluted share against $28,415,000 or $0.49 per diluted share a year ago. The development plan for evofosfamide is designed to investigate its safety and efficacy across a broad range of solid tumors and hematologic malignancies. Evofosfamide is being developed in therapeutic areas supported by preclinical and clinical data and where there is high unmet need for new anti-cancer agents. To date, evofosfamide has been evaluated in more than 1,500 patients with cancer. Threshold anticipates the following development activities related to company- and Merck KGaA, Darmstadt, Germany-sponsored clinical trials for evofosfamide in 2015: Continue to efficiently execute the two Phase 3 clinical trials of evofosfamide to allow for timely data analyses and to prepare for the potential submission of marketing applications, assuming the data from the trials are supportive; Continue to enroll the Phase 2 clinical trial of evofosfamide designed to support registration for the treatment of patients with non-squamous non-small cell lung cancer; Complete enrollment in the Phase 2 clinical trial of evofosfamide in combination with bortezomib (Velcade) and low-dose dexamethasone in patients with relapsed or refractory multiple myeloma; and Continue to enroll patients in the company's Phase 2 biomarker trial in patients with advanced melanoma.

Threshold Pharmaceuticals Inc. Presents at Cowen and Company 35th Annual Healthcare Conference, Mar-02-2015 04:50 PM

Threshold Pharmaceuticals Inc. Presents at Cowen and Company 35th Annual Healthcare Conference, Mar-02-2015 04:50 PM. Venue: The Boston Marriott Copley Place, Boston, Massachusetts, United States. Speakers: Harold E. Selick, Executive Chairman and Chief Executive Officer.

Threshold Pharmaceuticals, Inc. Announces New Preliminary Data from the Phase 2 Component of an Ongoing Company-Sponsored Phase 1/2 Trial of Th-302

Threshold Pharmaceuticals Inc. announced new preliminary data from the Phase 2 component of an ongoing Company-sponsored Phase 1/2 trial of TH-302, the company's lead investigational anticancer drug, in combination with the proteasome inhibitor bortezomib (Velcade) and low-dose dexamethasone ("TBorD") for the treatment of patients with relapsed/refractory multiple myeloma (MM). The median number of prior therapies was 8 (range, 4-12). The recommended phase 2 dose of TH-302 was determined to be 340 mg/m2 and no dose limiting toxicities were observed at this dose level. Partial responses (one very good partial response and one partial response) were observed in 2 of 7 (29%) evaluable patients overall and 2 of 4 (50%) evaluable patients at the recommended phase 2 dose of TH-302. The ongoing Phase 1/2 trial is investigating TH-302 and dexamethasone with or without bortezomib with respect to safety and tolerability, dose-limiting toxicities and the maximum-tolerated dose of TH-302, and preliminary efficacy in patients with relapsed/refractory MM. A total of 18 patients with relapsed/refractory MM have been enrolled in the Phase 2 TBorD component of the study as of November 17, 2014. Key data from TBorD dosing cohorts: boldPreliminary assessment of safety and tolerability No dose limiting toxicities were reported during Cycle 1 at TH-302 doses of 240 mg/m² or 340 mg/m². The maximum tolerated dose of TH-302 with dexamethasone had previously been established at 340 mg/m2, and dose escalation above that dose of TH-302 with dexamethasone plus bortezomib was not allowed.(1) Therefore, after 6 patients had been treated at 340 mg/m2 without a dose limiting toxicity, the recommended Phase 2 dose of TH-302 in TBorD was established at 340 mg/m2. Safety data were available for 8 of 9 patients. The most common Grade 3/4 hematological adverse events were thrombocytopenia (reported in 4 patients), anemia (reported in 2 patients), and lymphopenia (reported in 2 patients). Fatigue (reported in 5 patients; one Grade 3/4) and nausea (reported in 4 patients; one Grade 3/4) were the most common non-hematological adverse events. Five serious adverse events (SAEs) were reported in 4 patients. One SAE of thrombocytopenia was considered related to TH-302. Skin toxicity, an adverse event of interest with TH-302, was limited: a Grade 2 rash resulting in treatment delay was reported at the 240 mg/m2 dose of TH-302, and one Grade 2 skin lesion with no impact on treatment was reported at the 340 mg/m2 dose of TH-302. There were no deaths related to the study drug.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
THLD:US $4.40 USD -0.10

THLD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for THLD.
View Industry Companies
 

Industry Analysis

THLD

Industry Average

Valuation THLD Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact THRESHOLD PHARMACEUTICALS, please visit www.thresholdpharm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.